- Home
- MLNK vs BCRX Comparison
MLNK vs BCRX Comparison
Compare MLNK & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- BCRX
- Stock Information
- Founded
- MLNK 1998
- BCRX 1986
- Country
- MLNK United States
- BCRX United States
- Employees
- MLNK N/A
- BCRX N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLNK Technology
- BCRX Health Care
- Exchange
- MLNK Nasdaq
- BCRX Nasdaq
- Market Cap
- MLNK 1.8B
- BCRX 1.6B
- IPO Year
- MLNK 2021
- BCRX 1994
- Fundamental
- Price
- MLNK $22.19
- BCRX $7.49
- Analyst Decision
- MLNK Hold
- BCRX Strong Buy
- Analyst Count
- MLNK 6
- BCRX 5
- Target Price
- MLNK $23.50
- BCRX $15.60
- AVG Volume (30 Days)
- MLNK 205.3K
- BCRX 1.7M
- Earning Date
- MLNK 11-07-2024
- BCRX 11-04-2024
- Dividend Yield
- MLNK N/A
- BCRX N/A
- EPS Growth
- MLNK N/A
- BCRX N/A
- EPS
- MLNK N/A
- BCRX N/A
- Revenue
- MLNK $311,440,000.00
- BCRX $412,579,000.00
- Revenue This Year
- MLNK $5.98
- BCRX $38.01
- Revenue Next Year
- MLNK $7.39
- BCRX $19.04
- P/E Ratio
- MLNK N/A
- BCRX N/A
- Revenue Growth
- MLNK 3.96
- BCRX 29.92
- 52 Week Low
- MLNK $16.49
- BCRX $4.03
- 52 Week High
- MLNK $25.88
- BCRX $8.88
- Technical
- Relative Strength Index (RSI)
- MLNK 42.46
- BCRX 48.08
- Support Level
- MLNK $22.81
- BCRX $7.55
- Resistance Level
- MLNK $23.03
- BCRX $8.07
- Average True Range (ATR)
- MLNK 0.44
- BCRX 0.33
- MACD
- MLNK -0.12
- BCRX 0.00
- Stochastic Oscillator
- MLNK 11.83
- BCRX 36.19
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.